Skip to main content

Table 3 Simulated numbers of influenza vaccinations and outcomes in children and adults using base-case values

From: The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study

Vaccinations and outcomesa Children (0–17 years) Adults (18 years and over)
Scenario 1b Scenario 2c Difference Scenario 1b Scenario 2c Difference
Vaccinations
TIV 19,297,651 1,084,672 −18,212,979 180,955,563 180,955,563 0
LAIV 0 45,637,434 45,637,434 0 0 0
Total 19,297,651 46,722,106 27,424,455 180,955,563 180,955,563 0
Epidemiological outcomes
Infections 13,830,361 4,835,746 −8,994,615 (−65.0%) 45,033,115 30,122,649 −14,910,466 (−33.1%)
Symptomatic cases 9,252,511 3,235,114 −6,017,397 (−65.0%) 30,127,153 20,152,052 −9,975,101 (−33.1%)
  1. TIV trivalent inactivated influenza vaccine; LAIV live-attenuated influenza vaccine.
  2. aAll results are estimates for the 10-year evaluation period.
  3. bScenario 1: TIV immunisation at current age-specific vaccination coverage.
  4. cScenario 2: TIV immunisation of children 2 to 17 years of age is replaced by LAIV immunisation, with coverage increasing up to 50% in three annual steps.